OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells
Takashi Yahata, Abd Aziz Ibrahim, Ken-ichi Hirano, et al.
Haematologica (2020) Vol. 106, Iss. 2, pp. 483-494
Open Access | Times Cited: 22
Takashi Yahata, Abd Aziz Ibrahim, Ken-ichi Hirano, et al.
Haematologica (2020) Vol. 106, Iss. 2, pp. 483-494
Open Access | Times Cited: 22
Showing 22 citing articles:
The tumor microenvironment: shaping cancer progression and treatment response
Sharav Desai, Vipul P. Patel, Kunal Bhosle, et al.
Journal of Chemotherapy (2024), pp. 1-30
Closed Access | Times Cited: 13
Sharav Desai, Vipul P. Patel, Kunal Bhosle, et al.
Journal of Chemotherapy (2024), pp. 1-30
Closed Access | Times Cited: 13
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Hanieh Mojtahedi, Niloufar Yazdanpanah, Nima Rezaei
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 50
Hanieh Mojtahedi, Niloufar Yazdanpanah, Nima Rezaei
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 50
SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment
Ralf‐Peter Czekay, Craig E. Higgins, Hasan Basri Aydin, et al.
Cells (2024) Vol. 13, Iss. 10, pp. 796-796
Open Access | Times Cited: 5
Ralf‐Peter Czekay, Craig E. Higgins, Hasan Basri Aydin, et al.
Cells (2024) Vol. 13, Iss. 10, pp. 796-796
Open Access | Times Cited: 5
SOHO State of the Art Updates and Next Questions | Combination Therapy in Chronic Myeloid Leukemia in Chronic Phase
Alessandro Nanni Costa, Massimo Breccia
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Alessandro Nanni Costa, Massimo Breccia
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1
Abd Aziz Ibrahim, Taku Fujimura, Tomoko Uno, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Abd Aziz Ibrahim, Taku Fujimura, Tomoko Uno, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors
Alessandro Nanni Costa, Emilia Scalzulli, Ida Carmosino, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 2, pp. 189-202
Closed Access | Times Cited: 3
Alessandro Nanni Costa, Emilia Scalzulli, Ida Carmosino, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 2, pp. 189-202
Closed Access | Times Cited: 3
Plasminogen activating inhibitor‐1 promotes angiogenesis in cutaneous angiosarcomas
Kentaro Ohuchi, Ryo Amagai, Tetsuya Ikawa, et al.
Experimental Dermatology (2022) Vol. 32, Iss. 1, pp. 50-59
Closed Access | Times Cited: 14
Kentaro Ohuchi, Ryo Amagai, Tetsuya Ikawa, et al.
Experimental Dermatology (2022) Vol. 32, Iss. 1, pp. 50-59
Closed Access | Times Cited: 14
Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
Kentaro Ohuchi, Yumi Kambayashi, Takanori Hidaka, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 18
Kentaro Ohuchi, Yumi Kambayashi, Takanori Hidaka, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 18
Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers
Taku Fujimura
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 4044-4044
Open Access | Times Cited: 13
Taku Fujimura
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 4044-4044
Open Access | Times Cited: 13
Pharmacological inhibition of PAI-1 alleviates cardiopulmonary pathologies induced by exposure to air pollutants PM2.5
Asish K. Ghosh, Saul Soberanes, Elizabeth Lux, et al.
Environmental Pollution (2021) Vol. 287, pp. 117283-117283
Open Access | Times Cited: 16
Asish K. Ghosh, Saul Soberanes, Elizabeth Lux, et al.
Environmental Pollution (2021) Vol. 287, pp. 117283-117283
Open Access | Times Cited: 16
Time to relapse in chronic lymphocytic leukemia and DNA-methylation-based biological age
Drew Nannini, Rene Cortese, Peter Egwom, et al.
Clinical Epigenetics (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 6
Drew Nannini, Rene Cortese, Peter Egwom, et al.
Clinical Epigenetics (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 6
miR-181a plays the tumor-suppressor role in chronic myeloid leukemia CD34 + cells partially via SERPINE1
Xiuyan Zhang, Wenjuan Ma, Wen Xue, et al.
Cellular and Molecular Life Sciences (2023) Vol. 81, Iss. 1
Open Access | Times Cited: 6
Xiuyan Zhang, Wenjuan Ma, Wen Xue, et al.
Cellular and Molecular Life Sciences (2023) Vol. 81, Iss. 1
Open Access | Times Cited: 6
Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor
Naoto Takahashi, Yoshihiro Kameoka, Makoto Onizuka, et al.
Cancer Medicine (2022) Vol. 12, Iss. 4, pp. 4250-4258
Open Access | Times Cited: 10
Naoto Takahashi, Yoshihiro Kameoka, Makoto Onizuka, et al.
Cancer Medicine (2022) Vol. 12, Iss. 4, pp. 4250-4258
Open Access | Times Cited: 10
Translating Senotherapeutic Interventions into the Clinic with Emerging Proteomic Technologies
Amit Kumar Dey, Reema Banarjee, Mozhgan Boroumand, et al.
Biology (2023) Vol. 12, Iss. 10, pp. 1301-1301
Open Access | Times Cited: 4
Amit Kumar Dey, Reema Banarjee, Mozhgan Boroumand, et al.
Biology (2023) Vol. 12, Iss. 10, pp. 1301-1301
Open Access | Times Cited: 4
Possible effects of plasminogen activator inhibitor‐1 on promoting angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoides
Taku Fujimura, Kentaro Ohuchi, Tetsuya Ikawa, et al.
Hematological Oncology (2024) Vol. 42, Iss. 1
Closed Access | Times Cited: 1
Taku Fujimura, Kentaro Ohuchi, Tetsuya Ikawa, et al.
Hematological Oncology (2024) Vol. 42, Iss. 1
Closed Access | Times Cited: 1
Plasminogen activator inhibitor type-1 is a negative regulator of hematopoietic regeneration in the adipocyte-rich bone marrow microenvironment
Kaito Harada, Takashi Yahata, Makoto Onizuka, et al.
Biochemical and Biophysical Research Communications (2021) Vol. 557, pp. 180-186
Closed Access | Times Cited: 8
Kaito Harada, Takashi Yahata, Makoto Onizuka, et al.
Biochemical and Biophysical Research Communications (2021) Vol. 557, pp. 180-186
Closed Access | Times Cited: 8
Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias
Xingjian Zhai, Xiaoyan Jiang
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1841-1841
Open Access | Times Cited: 4
Xingjian Zhai, Xiaoyan Jiang
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1841-1841
Open Access | Times Cited: 4
Production Enhancement of an Anticoagulant Trypsin Inhibitor from Oceanimonas sp. BPMS22 and Its Anti-cancer Activity
B.S. Harish, Mamilla R. Charan Raja, Santanu Kar Mahapatra, et al.
International Journal of Peptide Research and Therapeutics (2020) Vol. 27, Iss. 1, pp. 197-208
Closed Access | Times Cited: 4
B.S. Harish, Mamilla R. Charan Raja, Santanu Kar Mahapatra, et al.
International Journal of Peptide Research and Therapeutics (2020) Vol. 27, Iss. 1, pp. 197-208
Closed Access | Times Cited: 4
TM5614, an Inhibitor of Plasminogen Activator Inhibitor-1, Exerts an Antitumor Effect on Chronic Myeloid Leukemia
Katsuyuki Sasaki, Tohru Fujiwara, Tetsuro Ochi, et al.
The Tohoku Journal of Experimental Medicine (2022) Vol. 257, Iss. 3, pp. 211-224
Open Access | Times Cited: 3
Katsuyuki Sasaki, Tohru Fujiwara, Tetsuro Ochi, et al.
The Tohoku Journal of Experimental Medicine (2022) Vol. 257, Iss. 3, pp. 211-224
Open Access | Times Cited: 3
Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSCs) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs
Esther Sathya Bama Benjamin, Elizabeth Vinod, Raveen Stephen Stallon Illangeswaran, et al.
Cellular Signalling (2024) Vol. 116, pp. 111067-111067
Closed Access
Esther Sathya Bama Benjamin, Elizabeth Vinod, Raveen Stephen Stallon Illangeswaran, et al.
Cellular Signalling (2024) Vol. 116, pp. 111067-111067
Closed Access
Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1
Takashi Yahata, Abd Aziz Ibrahim, Taku Fujimura, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 1
Takashi Yahata, Abd Aziz Ibrahim, Taku Fujimura, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 1
Therapeutic applications of PAI-1 inhibitor for the treatment of hematological malignancies
Takashi Yahata
Japanese Journal of Thrombosis and Hemostasis (2020) Vol. 31, Iss. 3, pp. 310-315
Open Access
Takashi Yahata
Japanese Journal of Thrombosis and Hemostasis (2020) Vol. 31, Iss. 3, pp. 310-315
Open Access
